Turning Capability into
Compounding Value
Financial Capital
Deploying financial resources to generate long-term value through strategic investments.
- Equity: ₹ 5,300 crore
- Debt: ₹ 2,397 crore
- Gross Block: ₹ 7,650 crore
Intellectual Capital
Strengthening innovation through R&D, securing patents and developing differentiated solutions.
- R&D investment: ₹ 282 crore
- R&D centres: 6
- R&D and quality team strength: 3,134
Manufactured Capital
Enabling scalable and integrated manufacturing and operational efficiency through technology-led process improvements.
- 15 manufacturing sites, including bio division
- 100% manufacturing sites are cGMP compliant
Social and Relationship Capital
Building stakeholder trust through transparent engagement and proactive responsiveness.
- CSR spend: ₹ 12.5 crore
- Regulatory and customer audits: 132
Human Capital
Cultivating a highly skilled team through targeted training and aligning their expertise with our vision.
- Total employees: 8,126
- Employee benefit expense: ₹ 895 crore
- Health and safety training: 1,11,941 man-hours
Natural Capital
Safeguarding natural resources by adopting sustainable sourcing and optimising operations.
- Energy from renewable sources: 1,17,375 GJ
- Energy from non-renewable sources: 48,63,278 GJ
- Water consumed: 10,46,969 KL
Vision
To be a leading player in offering integrated solutions for global pharmaceutical needs in creating a healthier world.
Mission
We constantly strive for innovation to enhance quality and to provide affordable, integrated pharmaceutical solutions to facilitate wellness and well-being across the globe.
Values
Our Pillars of Excellence
Business Division
- Small Molecules
- Bio
- API
- FDF
Business Activities
- Advance integrated development and manufacturing programmes
- Execute complex chemistry and commercial-scale production
- Supply high-quality APIs and formulations across global markets
- Strengthen long-term customer partnerships
- Expand capabilities across existing and emerging platforms
Innovate
Excel
Expand- Revenue: ₹ 6,813 crore
- EBITDA: ₹ 1,826 crore
- Market capitalisation: ₹ 536 billion
- Total dividend paid: ₹ 86 crore
- 244 patents granted
- 94+ launches across drug product (DP) and drug substance (DS)
- 12 billion tablets and capsules formulation (OSD)
- Zero incidents of product recall
- 11 ongoing growth projects [7 API, 2 FDF, 1 Fermentation, 1 Gene Therapy/ADC]
- 8,200 KL reactor capacity
- 275+ clients served
- ₹ 294 crore direct taxes paid
- Certified as great place to work
- 100% of employees received career development reviews
- Healthy and skilled workforce
- ‘BBB’ rated by MSCI ESG Rating
- S&P Global ESG Score of 81 (vs. PY: 73)
- 3,77,764 tCO₂e of Scope 1 Emissions
- 1,89,832 tCO₂e of Scope 2 Emissions
- 37,449 tonnes of waste recycled and re-used
- 2nd Consecutive year in S&P Global Yearbook
Enhanced shareholder returns through capital appreciation and dividend payout
Superior solutions, patent portfolio growth and expanded expertise
Increased efficiency through technological advancements in continuous manufacturing
Strengthened trust and collaboration with all stakeholders, including regulatory bodies
A more skilled workforce aligned with organisational goals through ongoing development
Reduced environmental impact through sustainable practices and operational efficiency
Impacted
Employees
Communities
Customers
Suppliers
Government / Regulatory Authorities
Investors